BEAT-DKD

BEAt-DKD, a unique public-private partnership under the auspices of Innovative Medicines Initiative (IMI), is committed to deliver better stratification of patients and more effective tools for use in innovative clinical trials, with the aim to improve prevention and management of DKD and establish a new paradigm for precision medicine in DKD... The overall goals of the Biomarker Enterprise to Attack DKD (BEAt-DKD) consortium are to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD... Diabetic kidney disease (DKD) is the most common form of chronic kidney disease (CKD). Presently, there are no means to effectively prevent or cure DKD, which has reached..

Primary location: Malmö Sweden